Supernova Partners II (SNII) Pre-Announces Rigetti Deal Approval
by Nicholas Alan Clayton on 2022-02-25 at 7:06am

Supernova Partners Acquisition Company II (NYSE:SNII) announced this morning that it expects to gain approval of its combination with quantum computing firm Rigetti with sufficient cash to close the deal on March 2.

The SPAC passed its redemption deadline yesterday and as a result it now expects to deliver $114.24 million from its trust supplemented by a $147.5 million PIPE, which is plenty to satisfy the transaction’s $165 million minimum cash condition. This amounts to about 67% of shares redeemed, which may not have looked great in earlier times, but it would be the third lowest redemption rate among the 21 SPACs that have held votes so far in 2022.

Supernova II shareholders are expected to approve the transaction’s final vote on Monday, February 28, and the combined company is expected to trade on the Nasdaq under the symbol “RGTI”.

The parties initially announced their $1.15 billion combination on October 6. Berkeley, California-based Rigetti Computing has developed scalable quantum computing chips and is working to deploy its machines in collaboration with several government and research institutions.

For Supernova II, these relatively low redemptions would come despite opening at $8 and closing at $9.05 on the day of its redemption deadline. This is perhaps a testament to the high performance of transactions in the quantum computing space. Its peer IONQ (NYSE:IONQ) continues to trade well since completing its combination with dMY III in October and closed Thursday at $15.60. DPCM (NYSE:XPOA), which has a pending combination with D-Wave, meanwhile last closed at $9.88.


ADVISORS

  • Deutsche Bank Securities Inc. is serving as exclusive financial advisor to Rigetti.
  • Cooley LLP is serving as legal counsel to Rigetti.
  • Morgan Stanley & Co. LLC is serving as exclusive financial advisor to Supernova II.
  • Latham & Watkins LLP is serving as legal counsel to Supernova II.
  • Morgan Stanley & Co. LLC and Deutsche Bank Securities Inc. served as placement agents to Supernova II for the PIPE financing.
  • Sidley Austin LLP served as counsel to the placement agents.

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved